Genmab | GEN - Equity Capital And Reserves


Genmab reported DKK5.85B in Equity Capital and Reserves for its fiscal quarter ending in December of 2025.





Equity Capital And Reserves Change Date
Agios Pharmaceuticals USD 1.11B 84M Mar/2026
Almirall EUR 1.49B 24.03M Dec/2025
Amarin USD 449.41M 9.87M Mar/2026
Amgen USD 9.19B 532M Mar/2026
argenx SE USD 7.32B 1.23B Dec/2025
AstraZeneca USD 47.33B 1.33B Mar/2026
Bayer EUR 28.85B 2.9B Mar/2026
BioMarin Pharmaceutical USD 6.21B 125.11M Mar/2026
Demant DKK 9.84B 446M Dec/2025
Exelixis USD 1.94B 225.57M Mar/2026
Fresenius Medical Care EUR 14.2B 13.95B Mar/2026
Genmab DKK 5.85B 96M Dec/2025
GlaxoSmithKline GBP 17.42B 1.05B Mar/2026
GN Store Nord DKK 10.12B 4.76B Mar/2026
GRIFOLS EUR 5.46B 171M Mar/2026
Hikma Pharmaceutical USD 2.59B 42M Dec/2025
Insmed USD 704.85M 34.12M Mar/2026
Lakefront Biotherapeutics EUR 3.25B 17.5M Mar/2026
Lonza CHF 9.13B 513M Dec/2025
Merck EUR 28.59B 344M Dec/2025
Novartis USD 38.93B 7.2B Mar/2026
Regeneron Pharmaceuticals USD 31.42B 166.7M Mar/2026
Roche Holding CHF 33.8B 758M Dec/2025
Sanofi EUR 72.81B 1.1B Mar/2026
UCB EUR 10.87B 1.18B Dec/2025